PAREXEL International Corporation (Nasdaq: PRXL) today announced that Peter Rietman has been appointed Vice President and Treasurer.

PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the first quarter ended September 30, 2000.

PAREXEL International Corporation (Nasdaq: PRXL) today announced that its Advanced Technology and Informatics Unit has been established as a wholly-owned subsidiary, called Perceptive Informatics, Inc.

PAREXEL International Corporation has just released an all-new and expanded edition of New Drug Development: A Regulatory Overview, what PAREXEL believes to be the most widely read reference on the U.S. drug development and regulatory process.

Expands Worldwide Network of Hospital-Based Services

PAREXEL International Corporation (Nasdaq: PRXL) today announced a collaborative agreement with Phenome Sciences, Inc. for the co-promotion of Metaprobe™ biomarkers for use in clinical research programs.

PAREXEL International Corporation (Nasdaq: PRXL) will release First Quarter 2001 financial results on Thursday, October 26, 2000 before the opening of trading.

PAREXEL International Corporation (Nasdaq: PRXL) today announced its purchase of a full-service clinical pharmacology unit in the United Kingdom from GlaxoWellcome.

PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the fourth quarter and fiscal year ended June 30, 2000.

Companies Will Offer Innovative Electronic Data Capture Solutions For Clinical Trials Management

Providing Innovative Cardiac Diagnostic Methods for Use in Clinical Trials

Barnett International Corporation, a subsidiary of PAREXEL International Corporation (Nasdaq:PRXL), announced today a new semester of clinical research training programs being offered at the following universities:

PAREXEL to Demonstrate Integration of ParXware™ Data Warehousing Capabilities and Spotfire’s Decision Analytics Platform, Spotfire.net™

PAREXEL International Corporation (Nasdaq: PRXL) introduced today ParXnet™, a comprehensive web portal that brings enterprise-wide information to the desktop.

KMI/PAREXEL, Inc., a subsidiary of PAREXEL International Corporation (Nasdaq:PRXL), announced the appointment of Ronald F. Tetzlaff, Ph.D., as President, effective June 1, 2000.

PAREXEL International Corporation (Nasdaq: PRXL) today announced that James F. Winschel has been appointed Senior Vice President and Chief Financial Officer.

KMI/PAREXEL, Inc., a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), recently appointed Paul B. Conlon to the position of Director of Training and Technical Support based in the company’s Atlanta, Georgia facility.

PAREXEL International Corporation (Nasdaq: PRXL) announced today that a complaint has been filed against it in connection with the proposed merger with Covance, Inc. which was terminated in June of 1999.

-Joseph Eagle Leaving PAREXEL, But Will Remain External Director-

PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the third quarter ended March 31, 2000.

-Provides expertise to enhance safety monitoring of marketed pharmaceuticals-

Barnett International Corporation, a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), announced today the successful completion of the first ever Interactive Internet Training (IIT) for pharmaceutical clinical research professionals.

Companies to Offer Expanded Expertise in Clinical Evaluation of Stroke Treatments

PAREXEL International Corporation (Nasdaq: PRXL) announced today that Novartis, a key client, has reduced the amount of work currently outsourced to the PAREXEL Clinical Research Services (CRS) business unit, due to NovartisÕ reprioritization of its research pipeline.

PAREXEL International Corporation (Nasdaq: PRXL) today announced that it has appointed Mark T. Beaudouin as Vice President and General Counsel.

PAREXEL International Corporation (Nasdaq: PRXL) announced today that its wholly owned subsidiary, PAREXEL International Ltd., has entered into a collaborative research agreement with the Central Sheffield University Hospitals NHS Trust (CSUH), a research and teaching institution, located in the United Kingdom.

PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the second quarter ended December 31, 1999.

PAREXEL International Corporation (Nasdaq: PRXL) announced today that it has entered into a collaborative agreement with Pediatric Clinical Trials International, Inc.

Barnett International Corporation, a subsidiary of PAREXEL International Corporation (Nasdaq:PRXL), announced today a new semester of clinical research training programs being offered at the following universities: Villanova University, Georgetown University, University of North Carolina, Northwestern University, Boston College, and the University of San Diego.